ImmunityBio Future Growth
Future criteria checks 5/6
ImmunityBio is forecast to grow earnings and revenue by 64.1% and 47.8% per annum respectively while EPS is expected to grow by 64.8% per annum.
Key information
64.1%
Earnings growth rate
64.83%
EPS growth rate
| Biotechs earnings growth | 24.9% |
| Revenue growth rate | 47.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Jun 2026 |
Recent future growth updates
Recent updates
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Summary ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism. The Tokyo-172 BCG deal positions IBRX to resolve U.S. supply bottlenecks, enabling dual-source BCG infrastructure and global expansion, enhancing platform value. Read the full article on Seeking AlphaHere's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
Summary Anktiva received FDA approval in April 2024 for BCG-unresponsive NMIBC. Q3 revenue was $5.954 million, but high R&D and SG&A expenses led to an $80.253 million operational loss, with notable share dilution. Financial health shows a current ratio over 2.0, but high long-term debt and a $34 million monthly cash burn raise concerns. ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. IBRX remains a "sell" due to ongoing dilution, financial risks, and limited upside despite Anktiva's potential in NMIBC. Read the full article on Seeking AlphaEarnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 1,407 | 566 | 348 | 45 | 1 |
| 12/31/2027 | 452 | -168 | -14 | -129 | 3 |
| 12/31/2026 | 222 | -881 | -526 | -808 | 3 |
| 3/31/2026 | 141 | -855 | -299 | -294 | N/A |
| 12/31/2025 | 113 | -351 | -309 | -305 | N/A |
| 9/30/2025 | 83 | -349 | -325 | -320 | N/A |
| 6/30/2025 | 57 | -367 | -357 | -350 | N/A |
| 3/31/2025 | 31 | -409 | -377 | -370 | N/A |
| 12/31/2024 | 15 | -414 | -398 | -391 | N/A |
| 9/30/2024 | 7 | -588 | -434 | -421 | N/A |
| 6/30/2024 | 1 | -598 | -426 | -410 | N/A |
| 3/31/2024 | 0 | -601 | -413 | -389 | N/A |
| 12/31/2023 | 1 | -583 | -397 | -367 | N/A |
| 9/30/2023 | 1 | -458 | -384 | -342 | N/A |
| 6/30/2023 | 1 | -473 | -387 | -335 | N/A |
| 3/31/2023 | 1 | -430 | -406 | -347 | N/A |
| 12/31/2022 | 0 | -417 | -437 | -338 | N/A |
| 9/30/2022 | 1 | -400 | -409 | -318 | N/A |
| 6/30/2022 | 1 | -376 | -393 | -311 | N/A |
| 3/31/2022 | 1 | -370 | -364 | -289 | N/A |
| 12/31/2021 | 1 | -347 | -308 | -274 | N/A |
| 9/30/2021 | 0 | -323 | -283 | -260 | N/A |
| 6/30/2021 | 0 | -301 | -241 | -225 | N/A |
| 3/31/2021 | 1 | -264 | -210 | -201 | N/A |
| 12/31/2020 | 1 | -222 | -173 | -172 | N/A |
| 9/30/2020 | 2 | -176 | -136 | -132 | N/A |
| 12/31/2019 | 2 | -158 | N/A | -152 | N/A |
| 12/31/2018 | 3 | -84 | N/A | -67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IBRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: IBRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IBRX is expected to become profitable in the next 3 years.
Revenue vs Market: IBRX's revenue (47.8% per year) is forecast to grow faster than the US market (12.5% per year).
High Growth Revenue: IBRX's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IBRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 04:16 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunityBio, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |